Tuberculosis-Related Outcomes in Dermatologic Patients Receiving Systemic Therapy

Study limitation reported by the research below: “IL-23 inhibitors (as a separate class from IL-12/23) were present in some included studies but were grouped under IL-12/23 for some analyses; mechanism-specific estimates for IL-23 monotherapy may not be fully separable.”